These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]. Lynch JJ, Wallace AA, Stupienski RF, Baskin EP, Beare CM, Appleby SD, Salata JJ, Jurkiewicz NK, Sanguinetti MC, Stein RB. J Pharmacol Exp Ther; 1994 May; 269(2):541-54. PubMed ID: 7802864 [Abstract] [Full Text] [Related]
12. [Effect of the novel III class anti-arrhythmia preparation (AL-275) in experimental myocardium and sympathetic stimulation]. Kaverina NV, Lyskovtsev VV, Kishchuk EP. Eksp Klin Farmakol; 2001 May; 64(1):33-7. PubMed ID: 11544801 [Abstract] [Full Text] [Related]
13. Less heart is more. Zipes DP. Circulation; 2003 May 27; 107(20):2531-2. PubMed ID: 12777316 [No Abstract] [Full Text] [Related]
14. Protection against in vivo focal myocardial ischemia/reperfusion injury-induced arrhythmias and apoptosis by hesperidin. Gandhi C, Upaganalawar A, Balaraman R. Free Radic Res; 2009 Sep 27; 43(9):817-27. PubMed ID: 19579067 [Abstract] [Full Text] [Related]
15. Further electrophysiologic and anatomic correlates in a canine model of chronic myocardial infarction susceptible to the initiation of sustained ventricular tachyarrhythmias. Michelson EL, Spear JF, Moore EN. Anat Rec; 1981 Sep 27; 201(1):55-65. PubMed ID: 7305023 [Abstract] [Full Text] [Related]
16. [Pharmacology of antiarrhythmia agents: the new aspects]. Kaverina NV, Chichkanov GG. Eksp Klin Farmakol; 2003 Sep 27; 66(2):46-52. PubMed ID: 12962048 [Abstract] [Full Text] [Related]
17. In vitro preparation of infarcted myocardium. Sasyniuk BI. Environ Health Perspect; 1978 Oct 27; 26():233-42. PubMed ID: 720317 [Abstract] [Full Text] [Related]